Treatment of Female Sexual Dysfunction Due to Dyspareunia with Solid-State Vaginal Laser and Recombinant Platelet-Derived Epidermal Growth Factors: A Viable Possibility?
Objective: To examine the efficacy and safety of non-pharmacological and non-ablative options (or a combination of these) for postmenopausal dyspareunia. Mechanism: Narrative review on non-pharmacological and non-ablative options (or a combination of these) for postmenopausal dyspareunia. Findings i...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
IMR Press,
2023-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: To examine the efficacy and safety of non-pharmacological and non-ablative options (or a combination of these) for postmenopausal dyspareunia. Mechanism: Narrative review on non-pharmacological and non-ablative options (or a combination of these) for postmenopausal dyspareunia. Findings in Brief: Dyspareunia is the most bothersome symptom of the genitourinary syndrome of menopause, often complicated by decreased sexual interest and arousal. Solid-state vaginal laser (SSVL) and recombinant platelet-derived epidermal growth factors (RGFs) are new alternatives are new alternatives that improve female sexual dysfunction resulting from dyspareunia. Conclusions: SSVL is a new alternative the treatment of postmenopausal dyspareunia either alone or in combination with other alternatives with efficacy and safety similar to the classical options. |
|---|---|
| Item Description: | 0390-6663 10.31083/j.ceog5002040 |